State Board of Pharmacy			
Executive	As Passed By House	As Passed By Senate	As Enacted
PRXCD2 OARRS access			
R.C. 3796.32	R.C. 3796.32		R.C. 3796.32
Requires PRX to allow COM's Division of Marijuana Control, which is created by the bill, to access the Ohio Automated Rx Reporting System (OARRS) as needed to ensure compliance with the Medical Marijuana Control Program Law.	Same as the Executive.	No provision; see COMCD18.	Same as the Senate.
Fiscal effect: Minimal cost.	Fiscal effect: Same as the Executive.		
PRXCD3 Administration of immunizations by	pharmacists, pharmacy interns, and pharmacy techni	cians	
		R.C. 4729.41	
No provision.	No provision.	Authorizes certified pharmacy technicians and registered pharmacy technicians to administer immunizations in the same manner as pharmacy interns under current law.	No provision.
No provision.	No provision.	Authorizes pharmacists, interns, and technicians to administer immunizations beginning when a child is age 5, as opposed to the current law age limit of 7.	No provision.
No provision.	No provision.	Eliminates, for children under age 13, a requirement that their immunizations be prescribed (immunizations for COVID-19 and the flu do not require a prescription under current law or the amendment).	No provision.

State Board of Pharmacy			Main Operating Appropriations Bi H.B. 3
Executive	As Passed By House	As Passed By Senate	As Enacted
No provision.	No provision.	Requires, for each immunization administered to a child under age 18, that the pharmacist, intern, or technician inform the child's parent or legal guardian of the importance of well child visits with a pediatrician or other primary care provider, and refer patients when appropriate.	No provision.
		Fiscal effect: Potential minimal annual increase in PRX compliance inspection and enforcement costs.	

State Board of Pharmacy	7		Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Enacted
PRXCD4 **PARTIALLY VETOED	** Terminal distributor license exemptions		
		R.C. 4729.541, conforming changes in R.C. 4729.51, 4729.55	R.C. 4729.541, conforming changes in R.C. 4729.51, 4729.55
No provision.	No provision.	Adds the following exemptions from licensure as a terminal distributor of dangerous drugs: (1) a person who posses nitrous oxide for use as a direct ingredient food under federal regulations or for testi or maintaining a plumbing or HVAC system (2) a person who possesses medical oxyge sterile water, or sterile saline for direct patient administration or for installing or maintaining home medical equipment; an (3) [***VETOED: a person who possesses controlled substances and other dangerou drugs for dog training in conjunction with law enforcement agency.***]	t in ng m; en, ad
		Fiscal effect: Loss of 221 licenses and approximately \$82,720 in fee revenue collected biennially and credited to the Occupational Licensing and Regulatory Fund 4K90). Reduction in workload for P licensing and inspection staff.	

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Enacted
PRXCD5 Repeal of office-based opioid tre	eatment (OBOT) licensure		
		R.C. 4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30	R.C. 4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30
No provision.	No provision.	Eliminates PRX's licensure of terminal distributors of dangerous drugs with an office-based opioid treatment (OBOT) classification, which is required for facilities, clinics, and other locations providing OBOT to more than 30 patients.	Same as the Senate.
		Fiscal effect: Loss of 146 licenses and approximately \$64,240 in fee revenue collected biennially and credited to the Occupational Licensing and Regulatory Fun (Fund 4K90). Reduction in workload for PRI licensing and inspection staff.	
PRXCD1 Cash transfer from the Medical I	Marijuana Control Program Fund to the Drug Da	tabase Fund	
Section: 367.10	Section: 367.10	Section: 367.10	Section: 367.10
Permits the COM Director, upon request of the PRX Director, to certify an amount needed for the operation of PRX's drug database in each fiscal year. Permits the transfer of that amount from the Medical Marijuana Control Program Fund (Fund 5YSO), used by COM, to the Drug Databas Fund (Fund 5SGO), used by PRX.		Replaces the Executive provision with a provision that permits the PRX Director, in each fiscal year, to certify to the OBM Director an amount in cash to be transferred from Fund 5SY0 to Fund 5SG0, and upon Controlling Board approval, appropriates an transferred amounts. Makes technical correction to reference "Fund 5SY0" instead of "Fund 5YSO".	у

State Board of Pharmacy					Main Operating Appropriations Bill H.B. 33		
Executiv	ve	As Pass	sed By House	As Pass	ed By Senate	As Enac	ted
COMCD1	18 Division of Marijuana Control and trans	sfer of Med	ical Marijuana Control Program				
R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4729.80, 4729.86, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06	R.C.	121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4729.80, 4729.86, 4776.01; Section 525.20, 737.50; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06
(DMC) w COM to Control	the Division of Marijuana Control within COM and requires PRX and transfer the Medical Marijuana Program (MMCP) to DMC no later cember 31, 2023.	Same a	s the Executive.	Same a	s the Executive.	Same as	the Executive.
	hes a Superintendent of Marijuana to oversee DMC.	Same a	s the Executive.	Same a	s the Executive.	Same as	the Executive.
issued b the rem of medic remain a	s that licenses and registrations by COM and PRX remain in effect for ainder of their term and that forms cal marijuana approved by PRX approved unless that approval is later by DMC.	Same a	s the Executive.	Same a	s the Executive.	Same as	the Executive.
MMCP r amende review a	s that COM and PRX rules related to remain in effect until repealed or ed by DMC, but requires DMC to and propose revisions to existing rules I dispensaries no later than March 1,	Same a	s the Executive.	Same a	s the Executive.	Same as	the Executive.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33	
Executive	As Passed By House	As Passed By Senate	As Enacted	
Allows DMC to investigate alleged violations of the Medical Marijuana Law, including by subpoenaing documents and witnesses.	Same as the Executive.	Same as the Executive.	Same as the Executive.	
Requires PRX to grant DMC access to the Ohio Automated Rx Reporting System (OARRS) as needed to ensure compliance with the Medical Marijuana Law.	Same as the Executive.	Replaces the Executive provision with one that requires PRX, on receipt of a request from a designated representative of DMC, to provide to the representative information from OARRS relating to an individual who, or entity that, is the subject of an active investigation being conducted by DMC.	Same as the Senate.	
Makes conforming changes throughout the Revised Code.	Same as the Executive.	Same as the Executive.	Same as the Executive.	
No provision.	No provision.	No provision.	Allows holders of a provisional medical marijuana dispensary license who missed their initial operation deadline until December 31, 2023, to demonstrate compliance with dispensary operational requirements and begin operations. Delays any pending disciplinary actions against holders; and dismissed the actions altogether if the holder begins operations by that date.	
No provision.	No provision.	No provision.	Does all of the following in relation to the MMCP transfer: (1) provides for the transfer of PRX employees to COM, (2) authorizes OBM to make budget and accounting changes necessary to facilitate the transfer, (3) specifies that no action or proceeding on the effective date of the MMCP transfer is affected by the transfer, and (4) requires LSC to renumber rules of PRX regulating MMCP to reflect the transfer to COM.	

State Board of Pharmacy	Main Operating Appropriations B H.B. ;		
Executive	As Passed By House	As Passed By Senate	As Enacted
Fiscal effect: Increases costs for COM for overseeing PRX's portion of MMCP, and simultaneously reduces costs for PRX. The executive provides funding for these purpose under Fund 5SYO ALI 800650, Medical Marijuana Control Program.	Fiscal effect: Same as the Executive.	Fiscal effect: Same as the Executive.	Fiscal effect: Same as the Executive.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Enacted
MEDCD2 Legacy pain manageme	ent study committee		
	Section: 335.20	Section: 335.20	Section: 335.20
No provision.	Establishes the Legacy Pain Management Study Committee to study and evaluate the care and treatment of patients suffering from chronic or debilitating pain, in particular those who have been prescribed opioids for lengthy periods of time, often referred to as legacy patients.	Same as the House.	Same as the House.
No provision.	Includes the following as members of the committee: four members of the General Assembly, one representative of OhioMHAS, one representative of SMBO, one representative of PRX, one member representing patients, and one member representing prescribers.	Same as the House.	Same as the House.
No provision.	Requires the committee to consider several topics relating to legacy patients, including the availability of and access to pain management specialists in Ohio and the challenges associated with tapering opioid doses.	Same as the House.	Same as the House.
No provision.	Requires the committee, by December 1, 2024, to prepare and submit to the General Assembly a report of its recommendations for legislation to address the care and treatment of legacy patients.	Same as the House.	Same as the House.
	Fiscal effect: Minimal.	Fiscal effect: Same as the House.	Fiscal effect: Same as the House.

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33	
Executive	As Passed By House	As Passed By Senate	As Enacted	
MHACD21 Mobile-based opioid use disorder treat	ment			
Section: 337.95	Section: 337.95			
Requires OhioMHAS to operate a pilot program during FY 2024 and FY 2025 to provide opioid use disorder treatment to individuals in underserved regions selected by OhioMHAS, using medication units that are mobile.	Same as the Executive.	No provision.	No provision.	
Specifies that the purpose of the program is to extend access to medication-assisted treatment to areas of the state lacking licensed opioid treatment programs and qualifying practitioners.	Same as the Executive.	No provision.	No provision.	
Requires OhioMHAS to ensure that the services provided in mobile medication units used in the pilot program are those specified in relevant guidance issued by the U.S. Substance Abuse and Mental Health Services Administration.	Same as the Executive.	No provision.	No provision.	
Requires PRX, SMBO, and NUR and any other state agency that OhioMHAS determines may be of assistance in accomplishing the pilot program's purpose to provide assistance upon request from OhioMHAS.	Same as the Executive.	No provision.	No provision.	
Requires OhioMHAS to develop a plan for implementing and evaluating the pilot program within 60 days of the section's effective date.	Same as the Executive.	No provision.	No provision.	

State Board of Pharmacy			Main Operating Appropriations Bill H.B. 33
Executive	As Passed By House	As Passed By Senate	As Enacted
Requires OhioMHAS to complete a report of the findings obtained from the program within six months after the conclusion of the pilot program.	Same as the Executive.	No provision.	No provision.
Earmarks \$750,000 in each fiscal year in GRF ALI 336504, Community Innovations, to operate the pilot program.	Same as the Executive.	No provision.	No provision.